Skip to main content

Peer Review reports

From: Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies

Original Submission
21 Dec 2022 Submitted Original manuscript
12 Jan 2023 Reviewed Reviewer Report
23 Jan 2023 Reviewed Reviewer Report
24 Feb 2023 Author responded Author comments - Xingsheng Hu
Resubmission - Version 2
24 Feb 2023 Submitted Manuscript version 2
28 Feb 2023 Reviewed Reviewer Report
3 Mar 2023 Reviewed Reviewer Report
14 Mar 2023 Author responded Author comments - Xingsheng Hu
Resubmission - Version 3
14 Mar 2023 Submitted Manuscript version 3
6 Apr 2023 Author responded Author comments - Xingsheng Hu
Resubmission - Version 4
6 Apr 2023 Submitted Manuscript version 4
Publishing
14 Apr 2023 Editorially accepted
28 Apr 2023 Article published 10.1186/s12916-023-02865-z

You can find further information about peer review here.

Back to article page